Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Rhea-AI Summary

Scinai (Nasdaq: SCNI) secured expanded Israel Innovation Authority support for its robotic aseptic fill & finish program, enabling use of the full approved grant of NIS 5 million over two years, ~66% non-dilutive. Validation is targeted for completion in Q3 2026.

The investment supports acquisition and validation of a robotic-arm system aligned with EU GMP Annex 1 and complements Scinai's recent Recipharm Israel acquisition and strategic commercial collaboration to create an integrated two-site CDMO platform.

Positive

• Grant of NIS 5 million over two years, ~66% non-dilutive
• Validation of robotic aseptic system targeted for Q3 2026
• Integrated two-site CDMO platform after Recipharm Israel acquisition
• Commercial collaboration with Recipharm provides pathway to global manufacturing

Negative

• Further IIA CAPEX support is conditional on Israel's 2026 state budget
• Full grant utilization limited to a two-year program period

News Market Reaction – SCNI

+5.94%

4 alerts

+5.94% News Effect

+6.3% Peak Tracked

+$167K Valuation Impact

$3M Market Cap

0.1x Rel. Volume

On the day this news was published, SCNI gained 5.94%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $167K to the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Program grant budget: NIS 5 million Non-dilutive portion: 66% Program duration: 2 years +2 more

5 metrics

Program grant budget NIS 5 million Total approved budget for robotic aseptic fill & finish program over two years

Non-dilutive portion 66% Share of NIS 5 million program budget funded on a non-dilutive basis

Program duration 2 years Timeline for the robotic aseptic fill & finish support program

Validation target Q3 2026 Targeted completion of robotic aseptic system validation

State budget year 2026 Potential new IIA CAPEX program tied to Israel’s 2026 state budget

Market Reality Check

Price: $0.9100 Vol: Volume 48,335 is 63% abov...

high vol

$0.9100 Last Close

Volume Volume 48,335 is 63% above the 20-day average (29,673). high

Technical Price at 0.859, trading below the 200-day MA of 1.54 and far under the 6.18 52-week high.

Peers on Argus

SCNI gained 17.67% while peers showed mixed moves: GTBP down 3.58%, VRAX up 7.63...

1 Up 1 Down

SCNI gained 17.67% while peers showed mixed moves: GTBP down 3.58%, VRAX up 7.63%. This points to a stock-specific reaction rather than a broad biotech move.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Acquisition & collaboration	Positive	+2.9%	Closed Recipharm Israel acquisition and signed strategic Recipharm collaboration.
Jan 07	Industry roundtable	Neutral	-3.2%	CEO to co-lead biopharma manufacturing roundtable at HealthIL Week 2026.
Dec 02	Nine-month results	Positive	+3.0%	Reported revenue growth, lower R&D spend, and highlighted CDMO and grant progress.
Oct 06	IIA grant award	Positive	+1.9%	Non-dilutive IIA grant to expand small-batch sterile fill-and-finish capacity.
Sep 02	H1 2025 earnings	Positive	+0.7%	H1 2025 results with CDMO revenue growth and capital raise strengthening balance sheet.

Pattern Detected

SCNI has generally traded higher on CDMO expansion, grants, and deal news, with only one recent divergence on a neutral corporate event.

Recent Company History

Over the past six months, SCNI has repeatedly highlighted expansion of its CDMO platform and funding support. On Sep 2, 2025, H1 2025 results showed growing CDMO revenues and a strengthened balance sheet. Subsequent IIA grant news on Oct 6, 2025 and nine‑month 2025 results on Dec 2, 2025 reinforced this CDMO and grant-backed strategy. The Feb 17, 2026 acquisition of Recipharm Israel added a second site and a strategic collaboration. Today’s expanded IIA support for a robotic aseptic platform fits this ongoing CDMO build-out narrative.

Market Pulse Summary

The stock moved +5.9% in the session following this news. A strong positive reaction aligns with SCN...

Analysis

The stock moved +5.9% in the session following this news. A strong positive reaction aligns with SCNI’s pattern of trading higher on non-dilutive grant support and CDMO expansion news. Today’s update activates the full NIS 5 million program budget with 66% non-dilutive funding and targets validation in Q3 2026. Past IIA grants and the Recipharm acquisition were also followed by gains, but the stock still traded well below its 6.18 52-week high, underscoring execution and funding risks around the broader build-out.

Key Terms

aseptic fill & finish, cdmo, eu gmp annex 1, sterile manufacturing, +1 more

5 terms

aseptic fill & finish technical

"its project to advance a robotic aseptic fill & finish platform has been approved"

Aseptic fill & finish is the controlled process of putting a sterile drug or vaccine into its final container (vials, syringes, or bags) and sealing it without introducing contamination. Think of it like bottling sterile water in an ultra-clean factory: if the room, tools, or procedure aren’t perfect, the whole batch can be ruined. Investors care because capacity, quality controls, and regulatory approval of this step determine how quickly a product can be supplied, generate revenue, and avoid costly recalls or delays.

cdmo technical

"expand and modernize its CDMO capabilities following the recent acquisition"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

eu gmp annex 1 regulatory

"system designed to align with EU GMP Annex 1 standards."

A EU GMP Annex 1 is the European regulatory rulebook that sets detailed requirements for making sterile medicines and biologics, covering facility design, cleanrooms, equipment, processes and testing. Investors should care because compliance affects a manufacturer's ability to sell products, avoid shutdowns or recalls, and incur capital or operating costs — similar to how a building code determines whether a structure can be legally occupied and insured.

sterile manufacturing technical

"Robotic aseptic processing significantly reduces human intervention in sterile manufacturing"

Sterile manufacturing is the controlled production of medical products in an environment designed to prevent any microbial or particulate contamination, typically required for injectables, biologics and surgical supplies. It matters to investors because maintaining sterile conditions affects a company’s ability to get regulatory approval, avoid costly recalls, scale output and meet demand — like running a sealed, germ-free kitchen where any slip can spoil the whole batch.

capex financial

"new IIA program intended to support industrial CAPEX investments"

Capex, short for capital expenditures, refers to the money a company spends to buy, upgrade, or maintain physical assets such as buildings, equipment, or technology. It matters to investors because these investments can help a company grow and improve its long-term performance, but they also represent significant costs that can impact profitability and cash flow.

AI-generated analysis. Not financial advice.

JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic fill & finish platform has been approved for expanded support.

With this update, Scinai is now utilizing the full approved grant budget for the program, totaling NIS 5 million over two years, approximately 66% of which is non-dilutive funding.

The program supports the acquisition and validation of a fully automated, versatile robotic-arm aseptic fill & finish system designed to align with EU GMP Annex 1 standards. Validation of the system is targeted for completion in the third quarter of 2026.

The investment forms part of Scinai's broader strategy to expand and modernize its CDMO capabilities following the recent acquisition of Recipharm Israel Ltd. and the signing of a strategic commercial collaboration agreement with Recipharm. Together, the Jerusalem biologics facility and the newly acquired Yavne small-molecule site establish an integrated two-site development and manufacturing platform, while the Recipharm collaboration provides a defined pathway for clients to graduate from early clinical development to late-stage and commercial manufacturing within Recipharm's global network.

Robotic aseptic processing significantly reduces human intervention in sterile manufacturing, enhances reproducibility, and strengthens contamination control. The system is expected to expand Scinai's clinical manufacturing capabilities at its Jerusalem site and further reinforce its positioning as a technology-driven CDMO partner for emerging biotech companies.

"The expanded support from the Israel Innovation Authority strengthens our ability to invest in next-generation sterile manufacturing capabilities while maintaining disciplined capital allocation," said Amir Reichman, Chief Executive Officer of Scinai. "Following the Recipharm Israel acquisition and the launch of our commercial collaboration framework, we are focused on scaling our two-site CDMO platform and enhancing the technological depth of our biologics offering. Maximizing non-dilutive funding remains a core component of that strategy."

Elad Mark, Chief Operating Officer of Scinai, added: "The robotic aseptic fill and finish platform represents a significant step forward in our sterile manufacturing capabilities. Automated aseptic processing reduces operator intervention, enhances batch consistency, and strengthens contamination control in alignment with EU GMP Annex 1 requirements. This investment enhances our ability to support complex biologics programs and aligns with the broader expansion of our development and manufacturing footprint."

The Company is monitoring the anticipated launch of a potential new IIA program intended to support industrial CAPEX investments, which would be subject to approval of Israel's 2026 state budget and formal announcement by the Authority. Subject to the availability of such non-dilutive support, Scinai would evaluate opportunities to further enhance capabilities at its Yavne small-molecule site in alignment with its CDMO expansion strategy.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline.

The Company's wholly owned CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies. It operates two sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne.

The CDMO supports external clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization, analytical methods development and GMP production.

Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance.

The CDMO unit engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.

In parallel, Scinai is advancing, through its R&D unit, a focused immunology pipeline, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The Company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation.

Company website: www.scinai.com

Company Contacts

Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include statements regarding, among other things, the expected benefits of the Share Purchase Agreement and Commercial Collaboration Agreement with Recipharm, the anticipated expansion and scaling of the Company's CDMO platform, the expected validation and timing of the robotic aseptic fill and finish system, the anticipated benefits of robotic aseptic processing, potential future participation in Israel Innovation Authority programs, and the Company's strategic and capital allocation plans. Words such as "expects," "intends," "plans," "believes," "may," "will," "anticipates," "estimates," "targets," and similar expressions are intended to identify forward-looking statements.

These statements are based on current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, without limitation: the risk that the expected benefits of the Share Purchase Agreement and Commercial Collaboration Agreement will not be realized; the risk that the Company will not successfully integrate or expand its CDMO operations; delays or challenges in the validation or commercialization of the robotic aseptic fill and finish system and its resulting effect on Scinai's clinical manufacturing capabilities; failure to obtain, or delays in obtaining, grants or other non-dilutive funding, including under the EU STEP program or potential Israel Innovation Authority programs; lower than anticipated revenues from the CDMO business; failure to secure new client agreements; risks relating to the Company's ability to maintain compliance with Nasdaq continued listing requirements; risks associated with the Company's need for additional capital; risks related to research and development activities, including delays in or unsuccessful results from preclinical or clinical studies; regulatory risks; and general market and economic conditions.

More detailed information regarding these and other risks and uncertainties is included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 7, 2025, and in the Company's subsequent filings with the SEC.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-announces-expanded-israel-innovation-authority-support-for-robotic-aseptic-fill--finish-platform-302697055.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What grant amount did Scinai (SCNI) receive from the Israel Innovation Authority on February 25, 2026?

Scinai received expanded support totaling NIS 5 million over two years. According to the company, about 66% of the grant is non-dilutive, funding acquisition and validation of a robotic aseptic fill & finish system.

When is Scinai (SCNI) targeting validation completion for its robotic aseptic fill & finish system?

Scinai is targeting validation completion in Q3 2026. According to the company, the timeline covers system acquisition, validation aligned with EU GMP Annex 1, and readiness for clinical manufacturing at Jerusalem.

How does the robotic aseptic platform affect Scinai's (SCNI) manufacturing capabilities?

The platform is expected to expand clinical manufacturing and reduce human intervention. According to the company, automated aseptic processing improves reproducibility, contamination control, and supports complex biologics programs at the Jerusalem site.

How does the Recipharm Israel acquisition relate to Scinai's (SCNI) CDMO strategy?

The acquisition creates an integrated two-site development and manufacturing platform. According to the company, the Jerusalem biologics and Yavne small-molecule sites, plus Recipharm collaboration, enable client progression to late-stage and commercial manufacturing.

What portion of the IIA grant to Scinai (SCNI) is non-dilutive and why does that matter?

About 66% of the NIS 5 million grant is non-dilutive. According to the company, maximizing non-dilutive funding preserves shareholder equity while supporting capital investment in sterile manufacturing capabilities.

Is further IIA CAPEX support for Scinai (SCNI) guaranteed for 2026 upgrades at Yavne?

Further IIA CAPEX support is not guaranteed and depends on budget approval. According to the company, any new program would be subject to Israel's 2026 state budget and formal announcement by the Authority.